Ckd Bio (063160.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7063160006

Price
12,200.00 KRW
Market cap
66.93 bn KRW
P/E (2025)
–
P/S (2025)
0.42
Dividend yield
0.00 %
Net margin
-1.80 %
Return on equity (ROE)
-2.27 %
Return on assets (ROA)
-0.96 %

Ckd Bio financials

Fiscal year20242025
Revenue171.76 bn KRW160.07 bn KRW
Gross profit35.94 bn KRW28.78 bn KRW
Operating income10.95 bn KRW3.61 bn KRW
EBIT14.48 bn KRW2.65 bn KRW
Net income8.70 bn KRW-2.89 bn KRW
Diluted EPS – continuing operations1,586.02 KRW-526.50 KRW

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Ckd Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.